Table 1.
Baseline demographic and clinical characteristics of the PROMIS-II and NEPTUNE cohorts
| PROMIS-II Cohort N=121 |
NEPTUNE Pediatric Cohort N=40 |
NEPTUNE Adult Cohort N=40 |
|
|---|---|---|---|
| Sex | |||
| Male, n (%) | 79 (65) | 24 (60) | 137 (63) |
| Female, n (%) | 42 (35) | 16 (40) | 82 (37) |
| Age (years) | |||
| 8-12, n (%) | 65 (54) | 9 (23) | 0 (0) |
| 13-17, n (%) | 56 (46) | 31 (77) | 0 (0) |
| ≥18, n (%) | 0 (0) | 0 (0) | 219 (100) |
| Race | |||
| Caucasian, n (%) | 64 (53) | 15 (38) | 132 (60) |
| Black/African American, n (%) | 33 (28) | 20 (50) | 31 (14) |
| Asian, n (%) | 14 (12) | 1 (3) | 39 (18) |
| Other, n (%) | 10 (8) | 4 (10) | 17 (8) |
| Hispanic or Latino ethnicity, n (%) | 10 (8) | 7 (18) | 27 (12) |
| Disease duration | |||
| Incident (<30 days), n (%) | 56 (46) | 15 (38) | 72 (33) |
| Prevalent (≥30 days), n (%) | 65 (54) | 25 (62) | 147 (67) |
| Urine protein: creatinine ratio (g/g), median (IQR) | 5.2 (2.2, 8.6) | 2.6 (1.6, 7.3) | 4.1 (1.9, 6.8) |
| eGFR ml/min/1.73m2, median (IQR) | 110 (83, 134) | 88 (69, 108) | 65 (43, 96) |
| Edema present, n (%) | 90 (74) | 14 (35) | 124 (56) |
| Diagnosis | |||
| Minimal change disease, n (%) | 19 (16) | 12 (30) | 28 (13) |
| Focal segmental glomerulosclerosis, n (%) | 19 (16) | 18 (45) | 69 (32) |
| Membranous nephropathy, n (%) | 1 (1) | 1 (3) | 57 (26) |
| Other glomerular disease, n (%) | 16 (13) | 9 (23) | 65 (30) |
| Nephrotic Syndrome, not otherwise classified*, n (%) | 66 (55) | 0 (0) | 0 (0) |
Counts presented as n (%), Continuous variable presented as Median (Interquartile range)
*
In children, nephrotic syndrome is commonly treated based on clinical signs in the absence of a kidney biopsy informed diagnosis